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p<0.001) compared to those with control BRS group (total length <
60mm). The main target vessel in the FPJ group was the LAD (80.0%).
The incidence of periprocedural myocardial infarction (as deﬁned by a
creatinine kinase (CK) >2 times the upper limit of normal in addition
to a CK-MB elevation) was higher in the FPJ group (FPJ 16.1% vs.
control BRS group 8.8%: p¼0.20). The incidence of major adverse
cardiac events (deﬁned as a combination of all-cause death, follow-up
myocardial infarction and target vessel revascularization) tended to
be higher in the FPJ group (FPJ 15.8% vs. control BRS group 9.4%:
p¼0.35) at 1-year follow-up. Deﬁnite scaffold thrombosis was
observed in 1 patient who was treated with a FPJ and stopped clopi-
dogrel at 2 months after PCI. The incidence of target lesion revascu-
larization (per lesion) was signiﬁcantly higher in the FPJ group (FPJ
12.5% vs. control BRS group 5.0%: p¼0.01).
CONCLUSIONS The incidence of periprocedural MI and TLR was
higher in the FPJ group. FPJ treatment for diffuse long lesions appears
to be feasible taking into account the greater co-morbidity and lesion
complexity in this group.
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BACKGROUND The study has ascertained the long term beneﬁts of
coronary stenosis treatment with a bioresorbable scaffold eluting
everolimus.
METHODS In the ABSORB Cohort B multi-center, single arm trial, 45
patients (B1) and 56 patients (B2) underwent at different time points
serial quantitative coronary angiography (QCA), intra vascular ultra-
sound (IVUS) and optical coherence tomography (OCT). At 5 years 53
patients without Target Lesion Revascularization (TLR) were re-con-
sented to undergo a ﬁnal serial invasive imaging.
RESULTS Between 6 months/1 year and 5 years angiographic luminal
late loss (LLL) remained unchanged; B1 0.1419mm vs 0.130.33mm,
p¼0.7953, B2 0.230.28mm vs 0.180.32mm, p¼0.5685. When pa-
tients with a TLR were included LLL was 0.150.20 mm vs
0.150.24 mm, p¼0.8275 for B1 and 0.300.37 mm vs 0.320.48 mm,
p¼0.8204 for B2. For the entire cohort in-scaffold and in-segment
binary restenosis was 7.8% (5/64) and 12.5% (8/64), respectively. On
IVUS the minimum lumen area (MLA) of B1 decreased from
5.230.97 mm2 at 6 months to 4.891.81mm2 at 5 years (p¼0.04)
while it remained unchanged in B2 (4.950.91mm2 at 1 year,
4.841.28 mm2 at 5 years, p¼0.5). At 5 years the struts were no longer
discernable by OCT and IVUS. On OCT MLA in B1 decreased from
4.511.28mm2 at 6 months to 3.651.39mm2 at 5years (p¼0.01), while
it remained unchanged in B2 (4.351.09mm2 at 1 year, 4.121.38mm2
at 5 years, p¼0.24). In the entire Cohort B the 5-year Major Adverse
Cardiac Event (MACE) rate was 11.0% without any scaffold throm-
bosis, deﬁnite or probable.CONCLUSIONS At 5 years implantation of a bioresorbable scaffold
resulted in stable lumen dimensions, a low restenosis rate and a low
MACE rate.
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BACKGROUND Bioresorbable vascular scaffold (BVS) overlap is
frequent in long coronary lesions. Its impact into clinical outcomes is
unknown. We aims to compare the short and long-term clinical out-
comes between patients with overlap BVS implanted and those with
no-overlap BVS.
METHODS We analyzed the clinical outcomes of 1627 patients treated
with BVS in the Gauging coronary Healing with biOresorbable Scaf-
folding plaTforms in Europe (GHOST-EU) registry, according to im-
plantation of overlap scaffolds. Primary endpoint was patient oriented
composite endpoint (POCE) of: all-cause death, any myocardial
infarction (MI) and any percutaneous coronary intervention. Device
oriented composite endpoint (DOCE) of cardiac death, target-vessel
(TV) MI and TV-revascularization was also analyzed. Scaffold throm-
bosis, according to ARC deﬁnition, was also collected. Follow-up was
performed at 1 and 12 months.
RESULTS A total of 287 (17.6%) patients were treated with overlap
BVS. The remaining 1340 (82.4%) received BVS not overlap. The
overlap group had signiﬁcantly higher prevalence of diabetes melli-
tus, acute coronary syndrome, B2/C lesion type, SYNTAX score 22,
lesion length >34 mm, use of intracoronary imaging during implan-
tation, pre and post-dilatation, dual antiplatelet duration. At 1-year,
POCE was not different between the overlap vs. no-overlap groups
(13.6% vs. 14.6%, p ¼ 0.712), even after adjustment for the difference
between the two groups. The DOCE was also no different between the
two groups (5.6% vs. 5.8%, p¼0.540). Rate of scaffold thrombosis did
not differ either at 30 days (1.4% vs. 1.2%, p¼0.768) or at 1-year (2.1%
vs. 2.2%, p¼1.000)
CONCLUSIONS In “Real-world” clinical practice, BVS overlap does
not appear to have an impact on outcomes and in particular on scaf-
fold thrombosis, whose rate is not negligible.
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